Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16553375 | 0.84 | BACE1 (0.32) | BACE1 | |
| SCHEMBL16553376 | 0.84 | BACE1 (0.32) | BACE1 | |
| SCHEMBL16553374 | 0.84 | BACE1 (0.32) | BACE1 | |
| SCHEMBL25520998 | 0.77 | BACE1 (0.36) | BACE1 | |
| SCHEMBL13250486 | 0.77 | BACE1 (0.36) | BACE1 | |
| SCHEMBL13696122 | 0.76 | SMYD2 (0.32) | — | |
| SCHEMBL25417788 | 0.76 | BACE1 (0.36) | BACE1 | |
| SCHEMBL17808583 | 0.76 | BACE1 (0.36) | BACE1 | |
| SCHEMBL17522170 | 0.76 | KDM1A (0.36) | BACE1 | |
| SCHEMBL22283784 | 0.76 | BACE1 (0.36) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-09-21 | — | — | US | disclosed |
| US-9663524-B2 | Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors | CELGENE CAR LLC (BM) | 2017-05-30 | — | — | US | disclosed |
| US-20160046634-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | BACE1 3950/4885 |
| US-20160046634-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | BACE1 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.